New RSV vaccine study targets those over 80
NCT ID NCT07203365
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well the approved RSV vaccine Arexvy works in people aged 80 and older compared to those aged 60-65. Researchers will measure immune responses and side effects. The goal is to see if the vaccine protects the oldest and frailest adults as effectively as younger seniors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV IMMUNISATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Akademiskt specialistcentrum Studieenheten
RECRUITINGStockholm, 113 61, Sweden
-
Familjeläkarna SÄBO
RECRUITINGSaltsjöbaden, 13334, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.